News & Updates

A study in Singapore has provided a comprehensive update of the epidemiology of brain and spinal tumours managed surgically, helping guide future research on central nervous system (CNS) tumours.

Among patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy, those with a history of urinary tract stones appear to have poorer cancer-specific survival (CSS) and disease-free survival (DFS), according to a study.

Women using depot medroxyprogesterone acetate are at heightened risk of subsequent meningioma diagnosis, although the overall clinical risk is low, according to a retrospective study.

In advanced biliary tract cancer (BTC), progression-free survival (PFS) is moderately associated with overall survival (OS) both the trial- and patient-level analyses, while objective response rate (ORR) and disease control rate (DCR) show a low correlation.

A 3-year update from the phase III TOPAZ-1 study has shown sustained survival benefit and manageable safety with durvalumab plus gemcitabine and cisplatin (GemCis) relative to placebo among patients with advanced biliary tract cancer (BTC).

The combination of preoperative systemic therapy (PRST) with preoperative radiotherapy (PRRT) leads to significant improvements in overall survival (OS) among squamous cell lung cancer (SCLC) patients with pathologic N2, reports a study.

Treatment with the multitargeted tyrosine-kinase inhibitor zanzalintinib, when combined with atezolizumab, confers an overall survival benefit in previously treated metastatic colorectal cancer (mCRC), according to the phase III STELLAR-303 trial.

An artificial intelligence (AI) model using diffusion basis spectrum imaging (DBSI) can accurately predict clinically significant prostate cancer (csPCa) on biopsy and even reduce unnecessary prostate biopsies when combined with Prostate Imaging Reporting and Data System (PI-RADS), suggests a study.

In the frontline treatment of patients with HER2-expressing locally advanced or metastatic urothelial cancer, the combination of disitamab vedotin plus toripalimab yields a clinically meaningful and significant increase in survival compared with chemotherapy, as shown in the phase III RC48-C016 trial.